Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$322M Buy
3,396,963
+490,488
+17% +$44.3M 0.24% 81
2014
Q2
$250M Sell
2,906,475
-10,629
-0.4% -$808K 0.2% 117
2014
Q1
$204M Buy
2,917,104
+159,636
+6% +$12.6M 0.18% 124
2013
Q4
$233M Sell
2,757,468
-92,878
-3% -$7.35M 0.22% 96
2013
Q3
$220M Buy
2,850,346
+207,728
+8% +$14.6M 0.22% 87
2013
Q2
$155M Buy
+2,642,618
New +$159M 0.18% 115

Other funds holding CELG

UBS's CELG Position: Q3 2014 in Review

UBS increased its Celgene Corp (CELG) stake by 17% in Q3 2014, buying an estimated $44.3M and bringing the position to 3,396,963 shares worth $322M. The position accounts for 0.24% of the portfolio, ranked #81.

UBS first reported a position in CELG in Q2 2013 and has held it in 6 quarters since. 1,031 funds tracked by Wall St. Rank hold CELG as of Q3 2014.

  • UBS held 3,396,963 shares of Celgene Corp worth $322M as of Q3 2014.
  • UBS bought 490,488 Celgene Corp shares in Q3 2014, an estimated $44.3M.
  • Celgene Corp made up 0.24% of UBS's portfolio in Q3 2014, its #81 holding.
  • UBS first reported a position in Celgene Corp in Q2 2013 and has held it in 6 quarters since.
  • 1,031 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.